Journal: International Journal of Molecular Sciences
Article Title: Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer Models
doi: 10.3390/ijms252413672
Figure Lengend Snippet: Darolutamide in combination with radium-223 inhibits abnormal bone turnover. The levels of the bone formation marker ( A , B ) PINP and bone resorption marker ( C , D ) CTX-I were measured in blood samples collected from the saphenous vein of mice ( n = 7–9/group) 2 days prior to and 13, 27, and 41 days after the initiation of treatment. The mice were treated with vehicle; darolutamide (100 mg/kg, BID, p.o.); radium-223 (330 kBq/kg, Q4Wx2, i.v.); or a combination of darolutamide and radium-223 and were sacrificed on day 41 after the start of treatment, except for one mouse in the radium-223 monotherapy group, which was sacrificed on day 38. Plots describe mean and standard deviation (SD). Statistical analyses were performed using mixed models and model contrasts ( A , C ), ANOVA followed by contrasts ( B ), or a Kruskal–Wallis test followed by Dunn’s pairwise comparison test ( D ): *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Article Snippet: The markers were analyzed using a Human Kallikrein 3/PSA Quantikine ® enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN, USA) and Rat/Mouse PINP and RatLaps™ CTX-I ELISA kits (both from IDS Ltd., Boldon, UK).
Techniques: Marker, Standard Deviation, Comparison